American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Scott Bertram, a director at Becton Dickinson & Co. (NYSE:BDX), recently sold 700 shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission. The ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...